233 related articles for article (PubMed ID: 20732757)
1. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.
Studer G; Brown M; Salgueiro EB; Schmückle H; Romancuk N; Winkler G; Lee SJ; Sträuli A; Kissling B; Dummer R; Glanzmann C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):110-7. PubMed ID: 20732757
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
[TBL] [Abstract][Full Text] [Related]
3. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
5. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
Koutcher LD; Wolden S; Lee N
Am J Clin Oncol; 2009 Oct; 32(5):472-6. PubMed ID: 19487913
[TBL] [Abstract][Full Text] [Related]
6. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
7. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
Pryor DI; Porceddu SV; Burmeister BH; Guminski A; Thomson DB; Shepherdson K; Poulsen M
Radiother Oncol; 2009 Feb; 90(2):172-6. PubMed ID: 18976827
[TBL] [Abstract][Full Text] [Related]
8. StatBite: Radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11 institutions in Europe.
J Natl Cancer Inst; 2010 Jan; 102(2):75. PubMed ID: 20054017
[No Abstract] [Full Text] [Related]
9. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
10. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.
Studer G; Huguenin PU; Davis JB; Kunz G; Lütolf UM; Glanzmann C
Radiat Oncol; 2006 Mar; 1():7. PubMed ID: 16722599
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-related radiation dermatitis in head-and-neck cancer patients: in regard to Studer et al. (Int J Radiat Oncol Biol Phys in press).
Russi EG; Numico G; Merlano MC; Pinto C
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1278; author reply 1278-9. PubMed ID: 21353162
[No Abstract] [Full Text] [Related]
12. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab.
Bölke E; Gerber PA; Lammering G; Peiper M; Müller-Homey A; Pape H; Giro C; Matuschek C; Bruch-Gerharz D; Hoffmann TK; Gripp S; Homey B; Budach W
Strahlenther Onkol; 2008 Feb; 184(2):105-10. PubMed ID: 18259703
[TBL] [Abstract][Full Text] [Related]
13. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
[TBL] [Abstract][Full Text] [Related]
15. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT).
Studer G; Studer SP; Zwahlen RA; Huguenin P; Grätz KW; Lütolf UM; Glanzmann C
Strahlenther Onkol; 2006 May; 182(5):283-8. PubMed ID: 16673062
[TBL] [Abstract][Full Text] [Related]
16. Severe desquamation with skin necrosis: a distinct pattern of skin toxicity secondary to head and neck irradiation with concomitant cetuximab.
Billan S; Abdah-Bortnyak R; Kuten A
Isr Med Assoc J; 2008 Mar; 10(3):247. PubMed ID: 18494248
[No Abstract] [Full Text] [Related]
17. IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome.
Kim JW; Cho JH; Keum KC; Kim JH; Kim GE; Lee JY; Kim SK; Lee CG
Jpn J Clin Oncol; 2012 Dec; 42(12):1152-60. PubMed ID: 23077243
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Morganti AG; Mignogna S; Deodato F; Massaccesi M; Cilla S; Calista F; Serafini G; Digesú C; Macchia G; Picardi V; Caravatta L; Di Lullo L; Giglio G; Sallustio G; Piermattei A; Cellini N; Valentini V
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1073-80. PubMed ID: 20472342
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Peñagarícano JA; Moros EG; Ratanatharathorn V; Yan Y; Corry P
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1369-75. PubMed ID: 19625138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
